Resverlogix Corp.
CALGARY, September 1, 2011 -
Resverlogix Corp.
CALGARY, Alberta, January 25, 2011 - Resverlogix announced today that its lead drug RVX-208, a first in class
ApoA-I production drug, illustrated positive effects on an important
cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta
40 (Abeta40).
CHICAGO, November 17, 2010 - Resverlogix Corp.
CALGARY, Canada, September 30, 2010 - Resverlogix Corp.
HAMBURG and CALGARY, Canada, June 22, 2010 - Resverlogix Corp.
More News
- Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
- Cleveland Clinic Initiates Dosing in ASSERT Trial
- Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
- Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
